We are delighted to share that o2h Ventures has been shortlisted in two categories at the Enterprise Investment Scheme Association (EISA) Awards 2026.

o2h Ventures has been recognised as a finalist in the EIS Investment Manager of the Year. Specialist category, reflecting our commitment to supporting innovative early-stage life sciences and human health companies across the UK.

We have also been shortlisted for the EISA Impact Award, recognising the wider impact created through EIS-backed businesses. As part of our submission, we highlighted the progress of Atelerix, whose pioneering cell preservation technology has the potential to simplify the storage and transportation of biological materials, helping unlock new possibilities for advanced therapies and regenerative medicine.

Since launching in 2018, o2h Ventures has backed more than 35 life sciences ventures, helping founders translate breakthrough science into commercial and societal impact. Together, our portfolio companies have raised over $400 million in follow-on funding and continue to strengthen the UK life sciences ecosystem.

Sunil Shah, CEO of o2h Ventures, commented:

“We are delighted to be recognised by EISA through these two shortlistings. They reflect the quality of the founders we support and the dedication of the wider o2h team. We are particularly pleased to see the impact being created across our portfolio recognised and look forward to continuing our mission of backing science, supporting entrepreneurs and creating.”